These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

501 related articles for article (PubMed ID: 35917883)

  • 1. Novel therapeutic combinations with PARP inhibitors for small cell lung cancer: A bench-to-bedside review.
    Xiong J; Barayan R; Louie AV; Lok BH
    Semin Cancer Biol; 2022 Nov; 86(Pt 2):521-542. PubMed ID: 35917883
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.
    Allison Stewart C; Tong P; Cardnell RJ; Sen T; Li L; Gay CM; Masrorpour F; Fan Y; Bara RO; Feng Y; Ru Y; Fujimoto J; Kundu ST; Post LE; Yu K; Shen Y; Glisson BS; Wistuba I; Heymach JV; Gibbons DL; Wang J; Byers LA
    Oncotarget; 2017 Apr; 8(17):28575-28587. PubMed ID: 28212573
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PARP Inhibitor Activity Correlates with SLFN11 Expression and Demonstrates Synergy with Temozolomide in Small Cell Lung Cancer.
    Lok BH; Gardner EE; Schneeberger VE; Ni A; Desmeules P; Rekhtman N; de Stanchina E; Teicher BA; Riaz N; Powell SN; Poirier JT; Rudin CM
    Clin Cancer Res; 2017 Jan; 23(2):523-535. PubMed ID: 27440269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Positron-Emission Tomographic Imaging of a Fluorine 18-Radiolabeled Poly(ADP-Ribose) Polymerase 1 Inhibitor Monitors the Therapeutic Efficacy of Talazoparib in SCLC Patient-Derived Xenografts.
    Laird J; Lok BH; Carney B; Kossatz S; de Stanchina E; Reiner T; Poirier JT; Rudin CM
    J Thorac Oncol; 2019 Oct; 14(10):1743-1752. PubMed ID: 31195178
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Induced degradation of lineage-specific oncoproteins drives the therapeutic vulnerability of small cell lung cancer to PARP inhibitors.
    Kim C; Wang XD; Liu Z; Hao J; Wang S; Li P; Zi Z; Ding Q; Jang S; Kim J; Luo Y; Huffman KE; Pal Choudhuri S; Del Rio S; Cai L; Liang H; Drapkin BJ; Minna JD; Yu Y
    Sci Adv; 2024 Jan; 10(3):eadh2579. PubMed ID: 38241363
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.
    Owonikoko TK; Zhang G; Deng X; Rossi MR; Switchenko JM; Doho GH; Chen Z; Kim S; Strychor S; Christner SM; Beumer J; Li C; Yue P; Chen A; Sica GL; Ramalingam SS; Kowalski J; Khuri FR; Sun SY
    Cancer Med; 2014 Dec; 3(6):1579-94. PubMed ID: 25124282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Highlights of PAPR Inhibitors in Small Cell Lung Cancer].
    Zhang S; Liu J; Yang C; Zhang L; Li S; Bao H; Cheng Y
    Zhongguo Fei Ai Za Zhi; 2020 Sep; 23(9):806-810. PubMed ID: 32752582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PARP inhibitors for small cell lung cancer and their potential for integration into current treatment approaches.
    Barayan R; Ran X; Lok BH
    J Thorac Dis; 2020 Oct; 12(10):6240-6252. PubMed ID: 33209463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Poly(ADP-Ribose) Polymerase Inhibition in Small Cell Lung Cancer: A Review.
    Guo MZ; Marrone KA; Spira A; Scott SC
    Cancer J; 2021 Nov-Dec 01; 27(6):476-481. PubMed ID: 34904810
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Novel targeted strategies to overcome resistance in small-cell lung cancer: focus on PARP inhibitors and rovalpituzumab tesirine.
    Van Den Borg R; Leonetti A; Tiseo M; Giovannetti E; Peters GJ
    Expert Rev Anticancer Ther; 2019 Jun; 19(6):461-471. PubMed ID: 31148500
    [No Abstract]   [Full Text] [Related]  

  • 11. Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.
    Byers LA; Wang J; Nilsson MB; Fujimoto J; Saintigny P; Yordy J; Giri U; Peyton M; Fan YH; Diao L; Masrorpour F; Shen L; Liu W; Duchemann B; Tumula P; Bhardwaj V; Welsh J; Weber S; Glisson BS; Kalhor N; Wistuba II; Girard L; Lippman SM; Mills GB; Coombes KR; Weinstein JN; Minna JD; Heymach JV
    Cancer Discov; 2012 Sep; 2(9):798-811. PubMed ID: 22961666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
    Gadgeel SM
    Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CHK1 Inhibition in Small-Cell Lung Cancer Produces Single-Agent Activity in Biomarker-Defined Disease Subsets and Combination Activity with Cisplatin or Olaparib.
    Sen T; Tong P; Stewart CA; Cristea S; Valliani A; Shames DS; Redwood AB; Fan YH; Li L; Glisson BS; Minna JD; Sage J; Gibbons DL; Piwnica-Worms H; Heymach JV; Wang J; Byers LA
    Cancer Res; 2017 Jul; 77(14):3870-3884. PubMed ID: 28490518
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Darinaparsin (ZIO-101) enhances the sensitivity of small-cell lung cancer to PARP inhibitors.
    Cao GZ; Ma LY; Zhang ZH; Wang XL; Hua JH; Zhang JH; Lv Y; Zhang SB; Ou J; Lin WC
    Acta Pharmacol Sin; 2023 Apr; 44(4):841-852. PubMed ID: 36253561
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extensive-stage small-cell lung cancer: Current management and future directions.
    Yu Y; Chen K; Fan Y
    Int J Cancer; 2023 Jun; 152(11):2243-2256. PubMed ID: 36346100
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting DNA damage in SCLC.
    Foy V; Schenk MW; Baker K; Gomes F; Lallo A; Frese KK; Forster M; Dive C; Blackhall F
    Lung Cancer; 2017 Dec; 114():12-22. PubMed ID: 29173760
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nanoemulsion-Based Delivery of Fluorescent PARP Inhibitors in Mouse Models of Small Cell Lung Cancer.
    Gonzales J; Kossatz S; Roberts S; Pirovano G; Brand C; Pérez-Medina C; Donabedian P; de la Cruz MJ; Mulder WJM; Reiner T
    Bioconjug Chem; 2018 Nov; 29(11):3776-3782. PubMed ID: 30354077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Combination of the PARP Inhibitor Olaparib and the WEE1 Inhibitor AZD1775 as a New Therapeutic Option for Small Cell Lung Cancer.
    Lallo A; Frese KK; Morrow CJ; Sloane R; Gulati S; Schenk MW; Trapani F; Simms N; Galvin M; Brown S; Hodgkinson CL; Priest L; Hughes A; Lai Z; Cadogan E; Khandelwal G; Simpson KL; Miller C; Blackhall F; O'Connor MJ; Dive C
    Clin Cancer Res; 2018 Oct; 24(20):5153-5164. PubMed ID: 29941481
    [No Abstract]   [Full Text] [Related]  

  • 19. The emerging role of Schlafen-11 (SLFN11) in predicting response to anticancer treatments: Focus on small cell lung cancer.
    Scattolin D; Maso AD; Ferro A; Frega S; Bonanno L; Guarneri V; Pasello G
    Cancer Treat Rev; 2024 Jul; 128():102768. PubMed ID: 38797062
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting PARP proteins in acute leukemia: DNA damage response inhibition and therapeutic strategies.
    Padella A; Ghelli Luserna Di Rorà A; Marconi G; Ghetti M; Martinelli G; Simonetti G
    J Hematol Oncol; 2022 Jan; 15(1):10. PubMed ID: 35065680
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.